The UK and US have secured a significant bilateral deal that will keep no levies on UK drug exports going into the American market.
The Terms of the Accord
As part of the deal, the UK has committed to increase spending on pharmaceuticals through the public health system. This pledge guarantees that tariffs on these key products will be held at nothing for a duration of three years.
This development follows previous threats to significantly raise import taxes on patented pharmaceutical products, with figures discussed as high as double the cost.
"This arrangement with the UK bolsters the international landscape for innovative medicines and introduces much-needed balance to American-British pharmaceutical trade," an announcement said.
Commercial Impact
Medicines constitute one of the the United Kingdom's most significant export categories to the United States, which is by far the primary market for major UK drugmakers.
Trade data reveal that in the 12 months leading up to last September, the UK exported pharmaceutical products totaling billions to the US. This value accounted for nearly one-fifth of all goods exports in that span.
"This guarantee secures employment, boosts funding and facilitates the UK to emerge as a worldwide center for life sciences," the Business and Trade Secretary remarked.
Key NHS Changes
The pact involves several specific pledges from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it judges new therapies to be prohibitively costly by 25%.
- Higher Drug Budget: There is a target to raise total NHS spending on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
- Payback Limit: The amount pharmaceutical firms must pay back to the NHS to prevent overspending will be restricted at fifteen percent. Previously, refunds were more than twenty percent.
Broader Context
The deal comes amid a protracted tension between the drug companies and the ministers over spending levels and approval rates.
These tensions were exacerbated by claims that American consumers were paying several times more for the identical medicines than people in the Britain and the EU.
Over the last 18 months, several large manufacturing plans in the UK have been halted or cancelled, while multi-billion-dollar investments have been pledged toward American operations.
A senior figure acknowledged that the NHS must increase expenditure on drugs, noting that its expenditure on drugs had decreased as a proportion of its total funding over the last ten years.
